Stream Link 1 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1677791&tp_key=cad97656e5
Stream Link 8 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1677959&tp_key=0a41bc9ed6
Program Description
Managed care professionals play important roles in identifying patients with chronic obstructive pulmonary disease (COPD) who may be experiencing exacerbations on their current treatments. As newer targeted therapies enter the treatment landscape, managed care pharmacists can ensure access and effective use by providing opportunities for treatment escalation and optimizing the delivery of evidence-based care within health systems. Early identification, evidence-based treatment, and ongoing monitoring and disease management strategies are all approaches that can be incorporated when seeking to improve patient outcomes and lower the cost of care in COPD. In this activity, participants will review the clinical and economic burden of COPD, debate and discuss tactics to develop pathways for access to emerging therapies, and examine the safety and efficacy data for new agents in COPD management, especially for patients with an increased risk of exacerbation-related hospitalizations.
Target audience: Managed care pharmacists
Type of activity: Application
Release date: August 29, 2024
Expiration date: October 29, 2024
Time to complete activity: 1.0 hour
Learner level: Introductory
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the clinical and economic effects of chronic obstructive pulmonary disease (COPD) and the limitations of current standard-of-care therapy on preventing exacerbations.
- Differentiate new and emerging agents for the management of COPD based on mechanism of action, efficacy, and safety data in clinical trials with an emphasis on novel investigational medications to reduce exacerbations.
- Identify pathways to access for new agents in COPD and strategies that identify subsets of the patient population in whom these medications are most appropriate in order to reduce exacerbation-related hospitalizations and meet quality metrics.
Lori Ann Wilken, PharmD
Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois, Chicago College of Pharmacy
Director of Tobacco Dependence Center and Clinical Pharmacist
Pulmonary
University of Illinois Hospital and Health Sciences Systems
Chicago, Illinois
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-235-L01-P. The activity is available for CE credit through October 29, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Lori Ann Wilken, PharmD, has the following financial relationship with a commercial interest to disclose:
Consultant: Optum Rx
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms